How should nicotine vaping be regulated in Australia?

Author:

Mendelsohn Colin1ORCID,Wodak Alex2,Hall Wayne3

Affiliation:

1. General Practice Sydney Australia

2. Alcohol and Drug Service, St Vincents' Hospital Sydney Australia

3. National Centre for Youth Substance Use Research University of Queensland Brisbane Australia

Abstract

AbstractIn Australia, nicotine vaping products are regulated as prescription‐only medicines which can only be sold from a pharmacy, with the aim of preventing youth access and allowing use by adult smokers with a doctor's support. The Therapeutic Goods Administration has acknowledged that this policy has not achieved its goals. Instead, a thriving black market has developed which sells unregulated vape products to children and adults. Very few adult vapers use the legal prescription pathway. Regulation should find the optimal balance between facilitating legal access for adult smokers while restricting access by youth. The preferred approach is a tightly regulated consumer model with nicotine vaping products sold by licenced retail outlets with strict age‐of‐sale verification. Regulations should be proportionate to risk and reflect the lower harms of vaping relative to smoking. A consumer model would bring Australia into line with other Western countries and improve population health.

Publisher

Wiley

Subject

Health (social science),Medicine (miscellaneous)

Reference61 articles.

1. Nicotine without smoke: fighting the tobacco epidemic with harm reduction

2. Shape of the relapse curve and long-term abstinence among untreated smokers

3. Beyond “Safe and Effective”: The urgent need for high-impact smoking cessation medications

4. Australian Institute of Health and Welfare.National Drug Strategy Household Survey 2019. Drug Statistics series no. 32. PHE 270. Canberra AIHW. 2020. Available from:https://www.aihw.gov.au/reports/illicit‐use‐of‐drugs/national‐drug‐strategy‐household‐survey‐2019/contents/summary. Accessed 7 November 2022.

5. Electronic cigarettes for smoking cessation;Hartmann‐Boyce J;Cochrane Database Syst Rev,2022

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3